Access and reimbursement for Part B and Part D drugs. Implementation of provisions included in Subtitle B of PL.117-169-Inflation Reduction Act of 2022. Issues related to physician reimbursement under Medicare Part B drugs. Support for H.R. 1492/S. 839, To equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program. Policies related to the Most Favored Nation Drug Pricing Model
Source-reported fields
Filing overview
- Type
- 4th Quarter - Report
- Posted
- Jan 20, 2026
- Income
- $60,000.00
- Expenses
- Not reported
- Registrant
- THE MCMANUS GROUP
- Client
- AMGEN
- Filing UUID
- e4784c57-0bcd-41eb-b253-ce2a154a73f2
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.